These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 39004216)

  • 1. Using Sotatercept in the Care of Patients With Pulmonary Arterial Hypertension.
    Preston IR; Lewis D; Gomberg-Maitland M
    Chest; 2024 Sep; 166(3):604-611. PubMed ID: 39004216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Pulmonary Arterial Hypertension With Sotatercept: A Meta-Analysis.
    Uddin N; Ashraf MT; Sam SJ; Sohail A; Ismail SM; Paladini A; Syed AA; Mohamad T; Varrassi G; Kumar S; Khatri M
    Cureus; 2024 Jan; 16(1):e51867. PubMed ID: 38327917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Sotatercept and Approved Add-On Pulmonary Arterial Hypertension Therapies: A Systematic Review and Network Meta-Analysis.
    Pitre T; Desai K; Mah J; Zeraatkar D; Humbert M
    Ann Am Thorac Soc; 2024 Aug; 21(8):1194-1203. PubMed ID: 38820258
    [No Abstract]   [Full Text] [Related]  

  • 7. Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes.
    Nasrollahizadeh A; Soleimani H; Nasrollahizadeh A; Hashemi SM; Hosseini K
    Clin Cardiol; 2024 Jan; 47(1):e24173. PubMed ID: 37819149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
    McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM
    Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
    Waxman AB; Systrom DM; Manimaran S; de Oliveira Pena J; Lu J; Rischard FP
    Circ Heart Fail; 2024 May; 17(5):e011227. PubMed ID: 38572639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.
    Joshi SR; Atabay EK; Liu J; Ding Y; Briscoe SD; Alexander MJ; Andre P; Kumar R; Li G
    Front Cardiovasc Med; 2023; 10():1064290. PubMed ID: 36910526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotatercept: First Approval.
    Kang C
    Drugs; 2024 Jul; 84(7):857-862. PubMed ID: 38904927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
    Dumas SJ; Bru-Mercier G; Courboulin A; Quatredeniers M; Rücker-Martin C; Antigny F; Nakhleh MK; Ranchoux B; Gouadon E; Vinhas MC; Vocelle M; Raymond N; Dorfmüller P; Fadel E; Perros F; Humbert M; Cohen-Kaminsky S
    Circulation; 2018 May; 137(22):2371-2389. PubMed ID: 29444988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension.
    Auth R; Klinger JR
    Expert Opin Investig Drugs; 2023; 32(11):1025-1042. PubMed ID: 37881882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection.
    Li W; Quigley K
    Biochem Soc Trans; 2024 Jun; 52(3):1515-1528. PubMed ID: 38716930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective.
    Sahay S; Chakinala MM; Kim NH; Preston IR; Thenappan T; Mclaughlin VV
    Am J Respir Crit Care Med; 2024 Sep; 210(5):581-592. PubMed ID: 38984912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
    Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G
    Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension.
    Ait-Oudhia S; Jaworowicz D; Hu Z; Bihorel S; Hu S; Balasubrahmanyam B; Mistry B; de Oliveira Pena J; Wenning L; Gheyas F
    CPT Pharmacometrics Syst Pharmacol; 2024 Aug; 13(8):1380-1393. PubMed ID: 38812074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.